JNJ

Will Johnson & Johnson Earnings Top Pfizer and Merck?
Motley Fool
Sat, 10/12/13 - 11:58 am
JNJ
Cramer: Bet on Johnson & Johnson (video)
The Street
Sat, 10/12/13 - 11:54 am
JNJ
Why J&J Is Poised to Outperform
Motley Fool
Sat, 10/12/13 - 11:53 am
JNJ
Analysts' Actions: AIZ GLW JNJ LLY MRK
Yahoo/TheStreet.com
Fri, 10/11/13 - 09:35 am
JNJ
Eli Lilly
Merck
Pharmacyclics
The Big Bucks in Keeping Kids Focused
Bloomberg/Businessweek
Fri, 10/11/13 - 08:50 am
ADHD
Shire
Vyvanse
Novartis
JNJ
Europe
Earnings Preview: J&J to report 3Q results Tuesday
Yahoo/AP
Fri, 10/11/13 - 08:48 am
JNJ
earnings
AstraZeneca to co-promote J&J prostate cancer drug in Japan
Yahoo/Reuters
Fri, 10/11/13 - 08:47 am
JNJ
AstraZeneca
Japan
prostate cancer
abiraterone
Express Scripts stops covering key Big Pharma drugs on cost-effectiveness grounds
Fierce Pharma
Thu, 10/10/13 - 10:01 am
Express Scripts
Pfizer
Xeljanz
PBMs
JNJ
Stelara
GSK
Breo Ellipta
Johnson & Johnson poised to report solid Q3 results, says Bernstein
The Fly on the Wall
Thu, 10/10/13 - 08:11 am
JNJ
earnings
Knockoff Lust: AbbVie's $9 Billion-A-Year Humira
Seeking Alpha
Wed, 10/9/13 - 08:25 am
AbbVie
Humira
JNJ
Amgen
rheumatoid arthritis
J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail
Fierce Biotech
Tue, 10/8/13 - 09:41 am
JNJ
NS5A Inhibitors
GSK
hepatitis C
simeprevir
GSK2336805
Bill Weldon gets new chairman title at Chase Bank
Fierce Pharma
Fri, 10/4/13 - 12:43 pm
William Weldon
JNJ
Boehringer unit that makes Johnson & Johnson Doxil to shut, WSJ says
Yahoo/Fly on the Wall
Fri, 10/4/13 - 10:10 am
JNJ
Doxil
drug shortages
ovarian cancer
Boehringer Ingelheim
J&J makes an R&D splash with $42M venture play, biotech collaborations
Fierce Biotech
Thu, 10/3/13 - 05:35 pm
R&D
JNJ
Effimune
Merus
Novartis Venture Fund
Pfizer Venture Investments
Top 15 Drug Launch Superstars
Fierce Pharma
Thu, 10/3/13 - 10:35 am
drug launches
Eylea
Regeneron
Bayer
Tecfidera
Biogen Idec
Kalydeco
Vertex Pharmaceuticals
Kadcyla
Roche
Genentech
Victoza
Novo Nordisk
Gilenya
Novartis
Zytiga
JNJ
Yervoy
Bristol-Myers Squibb
Stribild
Gilead Sciences Xtandi
Medivation
Astellas
Afinitor
Amgen
Prolia
Stelara
Kyprolis
Xarelto
ONYX Pharmaceuticals
Dendreon: Time To Prove Itself Or Perish
Seeking Alpha
Thu, 10/3/13 - 09:11 am
Dendreon
prostate cancer
JNJ
Provenge
Medivation
J&J Says Boehringer Doxil Dispute May Cause Shortage
Bloomberg
Wed, 10/2/13 - 10:05 am
JNJ
Boehringer Ingelheim
drug shortages
Doxil
ovarian cancer
Which Alzheimer's Fighter Will Benefit From a Boost in Federal Funding?
Motley Fool
Mon, 09/30/13 - 04:29 pm
Alzheimer's disease
LY2886721
Eli Lilly
MK-8931
Merck
bapineuzumab
JNJ
solanezumab
Gammagard
Baxter International
Why This Health Care Giant Can Be a Core Holding
Motley Fool
Sun, 09/29/13 - 01:56 pm
JNJ
How Johnson & Johnson Plans to Win the Prostate Cancer Battle
Motley Fool
Sat, 09/28/13 - 12:17 pm
Zytiga
prostate cancer
JNJ

Pages